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ABSTRACT
Tubulin-targeting molecules are widely used cancer therapeutic agents. They 
inhibit microtubule-based structures, including the mitotic spindle, ultimately 
preventing cell division. The final fates of microtubule-inhibited cells are however often 
heterogeneous and difficult to predict. While recent work has provided insight into 
the cell response to inhibitors of microtubule dynamics (taxanes), the cell response 
to tubulin polymerization inhibitors remains less well characterized. Arylthioindoles 
(ATIs) are recently developed tubulin inhibitors. We previously identified ATI 
members that effectively inhibit tubulin polymerization in vitro and cancer cell growth 
in bulk cell viability assays. Here we characterise in depth the response of cancer 
cell lines to five selected ATIs. We find that all ATIs arrest mitotic progression, yet 
subsequently yield distinct cell fate profiles in time-lapse recording assays, indicating 
that molecules endowed with similar tubulin polymerization inhibitory activity in vitro 
can in fact display differential efficacy in living cells. Individual ATIs induce cytological 
phenotypes of increasing severity in terms of damage to the mitotic apparatus. That 
differentially triggers MCL-1 down-regulation and caspase-3 activation, and underlies 
the terminal fate of treated cells. Collectively, these results contribute to define the 
cell response to tubulin inhibitors and pinpoint potentially valuable molecules that 
can increase the molecular diversity of tubulin-targeting agents.
INTRODUCTION
Microtubules (MTs) are tubulin polymers 
indispensable for a variety of cellular functions, including 
cell morphology and motility, intracellular transport, and 
mitotic spindle assembly and dynamic activity. Mitotic 
spindle impairment arrests cells in early mitotic stages 
and can lead them to death. MTs are therefore among 
the best-validated targets in cancer therapy. MT-targeting 
agents have empirical therapeutic efficacy in a variety 
of cancers [see 1-6 for reviews]. Targeting non-tubulin 
mitotic factors (e.g., mitotic kinases, kinesins, motor 
proteins and other mitotic regulatory factors) also reduces 
cell proliferation and increases the death rate of cancer 
cells [7–10]. These approaches indicate that mitosis 
remains a valuable therapeutic target, encouraging efforts 
to rationalize the design of mitosis-targeting molecules 
and to understand the molecular bases of the cell response 
to these molecules [11].
Although a variety of tumor types are sensitive 
to MT-targeting agents, there are limitations to their 
therapeutic use. First, the expression profile of genes 
encoding MT-associated and MT-regulatory proteins found 
in different cancer types, and also within cells from a same 
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cancer, can synergize with, or antagonize, the effect of the 
drugs [12–14]. Second, tumor cells can develop resistance 
through diverse mechanisms [4, 15–17], involving not 
only the induction of efflux pump mechanisms implicated 
in multidrug resistance, but also the presence of mutations 
or differential expression of tubulin isotypes [18–21]. 
There is therefore a need to increase the molecular 
repertoire of potentially effective drugs.
Tubulin-targeting agents can either prevent MT 
polymerization or block their dynamic functions [1, 22]. 
In both cases dividing cells arrest in early mitosis with 
a defective mitotic apparatus and can eventually undergo 
death in mitosis, a molecularly distinct response from 
other cell death pathways [8, 23–25]. Cells treated with 
MT-targeting agents show variable propensity to undergo 
mitotic cell death, even among cells from genetically 
homogeneous cell populations [26–27]. Recent studies 
have sought to identify the determinants of mitotic 
death induction using in vivo imaging methods to follow 
up mitotic cell fates at the single cell level. In the case 
of Taxol (TAX), the prototype MT-stabilizing drug, a 
framework defined the “competitive networks” model has 
been formalized [28–30]. The model proposes that the 
heterogeneity in cell fates reflects the timing with which 
mitotic MT activity is blocked in individual cells: different 
cells would be endowed with a specific balance of pro-
death and pro-mitotic factors, depending on their stage 
when TAX “hits” them. The model predicts that TAX-
dependent block of MT dynamics in cells with abundant 
cyclin B1 determines sustained mitotic arrest, allowing 
time for the accumulation of pro-death factors that 
eventually induce cell death. Below a critical cyclin B1 
threshold, instead, mitotic arrest would not be sustained 
for long enough to accumulate death factors, facilitating 
mitotic slippage with unsegregated or mis-segregating 
chromosomes. c-Myc, BH3-only proteins and BCL-xL 
play critical roles in the final fate of TAX-treated cells 
[30]. In the case of drugs that inhibit MT assembly, the 
links between the mechanisms of MT inhibition, the 
induction of mitotic arrest and the onset of mitotic death 
remain less well clarified.
In the last years, various strategies have been 
employed to design diversified molecules and expand 
the molecular repertoire of anti-mitotic compounds. We 
previously reported the development of a novel class of 
MT-targeting agents based on an arylthioindole scaffold 
(ATI), which was designed to bind selectively the 
Colchicine-binding site on tubulin. Colchicine binding 
inhibitors are regarded as promising compounds in recent 
studies [31–32]. Structure-activity relationship (SAR) and 
biological studies of ATIs [33–36] pinpointed potentially 
interesting features: i) they competitively inhibit the 
binding of [3H]Colchicine to tubulin in vitro; ii) they 
show good chemical and metabolic stability in microsomal 
fractions from the human and mouse liver, as well as in 
whole injected mice [33], iii) they are small molecules 
(<400 kDa) compared to many MT-inhibitory drugs, such 
as Vinblastine (VBL, 900 kDa), and their low molecular 
mass is expected to facilitate their delivery to target organs 
and tissues in animal models [34], iv) they inhibit cell 
growth in a broad array of cancer cell lines, including 
taxane-resistant derived lines [33–35]. The methods 
employed in those studies measured the global cell cycle 
profiles and the overall toxicity at the level of bulk cell 
population, but have limitations. Importantly, they neither 
identified the modes with which cell death occurred, nor 
did they clarify whether ATIs induce generalized cell death 
or whether cells become sensitized to death specifically 
during mitosis. Here we take a step further and investigate 
in depth the response of cancer cell lines to five selected 
ATIs that proved promising in previous screening assays. 
Combined high-resolution immunofluorescence (IF) 
and single cell time-lapse recording methods are used to 
pinpoint their specific features as mitotic inhibitors and 
cell death inducers, and contribute to identify effectors 
required for the cell death response.
RESULTS
ATI compounds with similar in vitro tubulin-
binding activity arrest cell cycle progression 
with differential effectiveness in human 
cancer cell lines
The five ATIs examined in this work were designed 
based on the structure of the Colchicine-binding site on 
tubulin with molecular modeling back-up [37–38]. They 
were originally conceived as successive derivatives from 
a common structural scaffold (schematically shown in 
Figure 1A) and harbor substitutions at critical positions 
that confer improved metabolic stability and tubulin-
binding activity [details of design and synthesis, as well 
as methods employed to measure tubulin polymerization 
inhibition and competitive inhibition of labeled Colchicine 
binding to tubulin, by each ATI, are given in 33-35]. The 
five molecules were previously examined in separate 
studies as members of large ATI subfamilies: they were 
found to inhibit tubulin polymerization with comparable 
IC50 at low micromolar concentrations in vitro and 
competitively inhibited Colchicine binding to tubulin 
(in all cases above 75% inhibition [33–35], data are 
summarized in Figure 1B for ease of comparison). All 
five ATIs inhibited cell growth in a variety of cancer cell 
lines, including multidrug resistant cells [33–35]. The 
underlying mechanism(s), however, were not examined 
in depth.
To gain insight into their mode of action in restricting 
cancer cell growth, we first compared their effects on cell 
cycle progression in dose-response experiments. HeLa 
cell cultures were treated with increasing concentrations 
of each ATI for 24 hours (roughly covering the duration 
of one cell cycle), compared to VBL, a classical MT 
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polymerization inhibitor with a long-record of therapeutic 
use, and Combretastatin A-4 (CA-4), also binding to 
the Colchicine site on tubulin and under test in clinical 
trials. By FACS analysis, all ATIs arrested progression 
of 4C cells (G2+M phases), yet clear differences in their 
effectiveness emerged (Figure 2A): ATIs 10 and 5 induced 
arrest in (G2+M) phases only when used 100 nM, while 
lower concentrations were ineffective. The pyridinyl 
derivative ATI 57 displayed some inhibitory effect already 
at 50 nM concentration, accumulating almost 60% of 
treated cells in the (G2+M) phases. ATIs 33 and 44 proved 
most effective cell cycle inhibitors, both inducing almost 
complete (G2+M) arrest already at 20 nM, comparable to 
VBL and CA-4 (Figure 2A).
In parallel FACS assays we evaluated the overall cell 
death by measuring the frequency of annexin V-positive 
cells in ATI-treated cell samples. ATIs displayed a parallel 
hierarchy in cell death induction to that seen for cell cycle 
arrest: both ATI 33 and 44 induced a significant fraction 
of annexin V-reactive cells already when used 20 nM and 
plateaued thereafter, again comparable to VBL and CA-4. 
ATI 57 induced a comparable rate of cell death when used 
in a five-fold higher concentration (100 nM). ATI 5 and 
ATI 10, when used 100 nM, also induced cell death, albeit 
consistently lower than other ATIs (Figure 2B). Together 
these results indicate that ATI molecules with similar 
tubulin polymerization inhibitory IC50 in vitro display in 
fact remarkably different efficacy in intact cells, revealed 
by their differential effectiveness in inducing (G2+M) 
phase arrest and cell death. Given that HeLa cells lack 
functional p53, the data in Figure 2B also imply that ATI-
induced cell death is p53-independent.
We next investigated known cell death regulators in 
ATI-treated HeLa cell cultures. We first investigated pro-
survival members of the BCL-2 family. MCL-1 and BCL-
2 are both abundantly expressed in untreated healthy cells. 
In MT-damaged cells, down-regulation of MCL-1 protein 
abundance determines the length of mitotic arrest [39]. 
The abundance of MCL-1 is actually a critical determinant 
in the choice between either mitotic arrest, or slippage 
through the mitotic checkpoint and mitotic exit without 
proper chromosome segregation [40].
As expected, MCL-1 protein was abundant in 
DMSO-treated control cultures. VBL, TAX and ATIs 
Figure 1: Properties of selected ATIs in human cells. A. Schematic structure of the ATI scaffold. X, R1 and R2 represent positions 
in which specific substitutions were tested. B. Summary features of in vitro properties of five selected ATI molecules and of known MT-
targeting drugs used in this work (for details of compound design and in vitro testing see 33-35).
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dramatically down-regulated MCL-1 abundance, except 
ATI 5, which induced only a slight decrease in MCL-1 
abundance. Thus, ATI-induced cell death requires MCL-
1 down-regulation, as previously shown for classical 
MT-targeting agents [13, 39]. MCL-1 down-regulation 
(Figure 2C) was particularly strong in cultures treated 
with ATIs that induced effective (G2+M) phase arrest 
and cell death, i.e. 57, 44 and 33 (Figure 2B). We 
concomitantly observed changes in the electrophoretic 
mobility of BCL-2. TAX is known to induce BCL-2 
phosphorylation, which triggers its inactivation and hence 
cell death [41, 30]. In our experiments BCL-2 migrates 
as a single band in control cultures (corresponding to the 
hypophosphorylated, anti-apoptotic form), whereas all 
treatments but ATI 5 induce the appearance of a doublet, 
in which the upper band (phosphorylated, inactive) is 
most abundant.
Parallel with BCL-2 phosphorylation, all drugs up-
regulated the expression of the pro-apoptotic factor BAX. 
The increase was particularly evident with ATIs 57, 33 and 
Figure 2: Dose-dependent induction of cell cycle arrest and cell death by ATIs in HeLa cultures. A. Cell cycle profiles of 
HeLa cultures treated with known MT-targeting drugs and ATIs in the indicated concentrations, as determined by FACS assays of PI-stained 
cultures. Bars represent SD values calculated from 3 to 7 independent experiments per condition. B. FACS analysis of the overall induction 
of cell death by known MT-targeting drugs and ATIs, as determined by annexin V-FITC staining. As in A, bars represent SD values from 
3 to 7 experiments per condition. C. Western blot of HeLa cell extracts after 24h of treatment with the indicated drugs: pro-survival and 
pro-apoptotic proteins in each treatment are shown.
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44, and it was comparable to that induced by TAX and 
VBL.
Mitotic cell death is associated with caspase-8 
(CASP8), caspase-9 (CASP9) and caspase-3 (CASP3) 
activation [42], and pan-caspase inhibitors prevent cell 
death induction by MT-targeting drugs. CASP3, in 
particular, is activated by TAX [14], and also by ATI 5 
in Jurkat lymphoblast cells [36]. We asked whether ATIs 
activate CASP9 or CASP3. Active CASP9 (37-35 kDa) is 
an apical caspase, activated via processing of pro-caspase 
9 under death-inducing stimuli. We found that control 
cultures expressed only a faint trace of the 37 kDa active 
fragment, whereas TAX, VBL and all ATIs induced the 
active CASP9 form, indicating that CASP9 processing is a 
rapid response to ATI-dependent MT inhibition, including 
by the mildest ATI. We next analysed the effector caspase 
CASP3 using an antibody that selectively recognizes 
the 17 kDa processed fragment from procaspase-3. No 
processed product was detected in control cultures. In 
contrast, TAX, VBL and all ATIs consistently induced 
the processed, active CASP3 form. The increase in active 
CASP3 was particularly effective in response to ATIs 57, 
33 and 44.
Caspase-3 activity is required for ATI-induced 
mitotic cell death
The results indicate that all ATIs, but ATI 5, 
inactivate anti-apoptotic factors, particularly MCL-1, 
and activate pro-apoptotic factors, among which active 
CASP3 showed the most significant accumulation. 
CASP3 gene mutations occur in various human cancers 
[43–44]. We therefore wished to assess whether CASP3 
is not only implicated, but actually required for cell death 
induction by ATIs. To address this issue, we used MCF 
7 breast carcinoma cell lines, which are functionally 
null for CASP3 expression, as they harbour a missense 
mutation in the CASP3 gene that causes exon skipping and 
prevents CASP-3 mRNA translation [45]. These cells were 
compared to a paired isogenic MCF7 cell line, MCF7/
CASP3, engineered to re-express CASP-3 [46]. We treated 
both cell lines with ATIs 5, 10 and 57 (100 nM). ATIs 33 
and 44 were also tested at lower concentrations, based on 
their higher efficacy demonstrated in HeLa cells.
All ATIs arrested MCF7 cells in the (G2+M) phase 
(Figure 3A), similar to TAX and VBL. (G2+M) arrest 
was induced to a similar extent in the MCF7/CASP3 
reconstituted cell line, confirming that the presence or 
absence of CASP3 does not influence the induction of 
mitotic arrest in the presence of damaged MTs [47]. A 
striking difference emerged instead in the distribution of 
dead cells between the isogenic cell lines. MCF7 cells are 
reported to activate an alternative CASP6 and -7 pathway 
after DNA-damaging agents [46, 48]. We found that all 
five ATIs induced a low level of cell death (revealed 
by annexin V analysis) in MCF7 cultures (Figure 3B). 
Increasing their concentration did not increase cell death 
any further (data not shown). Biparametric FACS profiles 
of annexin V and propidium iodide (PI) uptake in non-
permeabilized cultures revealed that the low level of cell 
death observed in MCF7 cultures comprised cells with 
necrotic (PI permeable) and apoptotic-like features (high 
annexin V reactivity, low PI incorporation) in similar 
proportion. In MCF7/CASP3 cell cultures, instead, the 
death profile was shifted towards apoptosis, while the 
relative weight of necrosis was significantly reduced. The 
overall extent of cell death was generally higher in MCF7/
CASP3 and varied with the specific ATI, with ATIs 44 and 
33 being again the most effective compounds already at 50 
nM. Thus, CASP-3, though being dispensable for mitotic 
arrest, is required for activation of non-necrotic cell death 
by ATIs.
ATIs induce progressively severe dose-dependent 
MT damage in HeLa cells
The results thus far indicate that ATIs binding to the 
“Colchicine site”, and inhibiting tubulin polymerization 
with similar IC50 in vitro, are differentially effective in 
inducing mitotic arrest and cell death in cycling cells. To 
gain more insight into possible mechanisms underlying 
these differences, we compared the cytological effects 
of ATIs by immunofluorescence (IF) to alpha-tubulin, in 
HeLa cell cultures. All ATI treatments (24 hours) induced 
a high frequency of prometaphase-like figures with sparse 
condensed chromosomes (64-74%, depending on the 
ATI), while interphases were not visibly affected: thus, 
the (G2+M) enrichment depicted by FACS (Figure 2A) 
reflects genuine arrest in prometaphase, suggesting that 
all ATIs activated the spindle assembly checkpoint (SAC).
Individual ATIs induced cytological phenotypes 
of progressive strength (examples are shown in Figure 
4A, and quantified in Figure 4C) by IF analysis of alpha-
tubulin. Most severely damaged mitotic phenotypes were 
observed in cultures treated with ATI 33, in which most 
mitotic cells (negative for lamin B1 staining, not depicted) 
displayed condensed chromosomes and amorphous tubulin 
aggregates with a meshwork-like appearance (examples in 
Figure 4A, panels g-i). ATI 44 yielded a similar dramatic 
inhibition of tubulin assembly above 50 nM. Lowering its 
concentration to 20 nM induced a less severe phenotype, 
with sparse small tubulin foci visible as unstructured 
spots on a diffuse tubulin background (panel f). Similar 
patterns were observed with both CA-4 and VBL (20 nM, 
not shown), as well as ATI 57 (100 nM, panel e). Thus, 
ATIs 57, 44 and 33 induce extensive MT damage in a 
concentration-dependent manner.
ATI 10 (100 nM) induced the appearance of short 
MTs arranged in small radial asters (panel c). ATI 5 
(200 nM) yielded sparse tubulin foci and tiny asters 
in variable proportions (panel d). Lower doses (20-50 
nM) of both ATIs 5 or 10 caused milder phenotypes, 
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Figure 3: Caspase-3 requirement for non-necrotic cell death induction during mitotic arrest in MCF7 isogenic cell 
lines. A. FACS analysis of cell cycle phases in PI-stained MCF7 and MCF7/CASP3 isogenic cell cultures: histograms represent the % 
of cells with 4C DNA content after 24 hours-exposure to the indicated drugs. Both isogenic cell lines undergo G2+M arrest regardless of 
CASP3 function. B. FACS analysis of overall cell death induction. Left, exemplifying biparametric panels of annexin V reactivity vs cell 
density (forward scattering axis) in control cultures (DMSO) and after exposure to ATI 57. The histograms show the frequency of annexin 
V-reactive cells in isogenic cell lines: only MCF7/CASP3-reconstituted cell cultures induce significant cell death in response to ATIs. C. 
Biparametric analysis of isogenic cell cultures double-stained for annexin-V and PI after ATI exposure. Exemplifying panels on the left 
show the distribution of viable cells with low values of both PI and annexin V (DMSO-treated control), and of cells undergoing necrosis 
(high PI, low annexin V values), or apoptosis-like death (high annexin V). MCF7/CASP3 reconstituted cell cultures induce significant 
apoptotic-like death in response to MT-targeting treatments. For all assays, means and SD values were calculated from three independent 
experiments for each cell line.
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Figure 4: Mitotic phenotypes of increasing severity reveal a hierarchy in the strength of ATIs. A. Examples of MT-
inhibitory phenotypes induced by ATIs at the indicated concentrations in HeLa cell cultures. MTs are visualized by FITC-conjugated anti 
alpha-tubulin antibody (green) and chromosomes by DAPI staining of the DNA (blue). Mitotic phenotypes are arranged according to their 
increasing intensity. Bar, 10 μm. B. Deconvolved images of MT asters from HeLa cell cultures exposed to 100 nM ATI 10. Top panel, 
gamma-tubulin staining of MTOCs. Middle panel, CENP-A staining to visualize KTs. Bottom panel, Bub1 staining to depict KTs on which 
the SAC is active. In the central column, the merged images depict chromosomes stained in blue, alpha-tubulin in green and the third 
marker in red. For greater detail, the rightmost lane displays a 2.5x magnification of the boxed area. Bar, 10 μm. 
(Continued )
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most frequently multipolar spindles (panel b). Thus, 
the IF data collectively indicate that mitotic phenotypes 
generated by ATIs are dose-dependent and depict a 
hierarchical scale of MT damage induction in HeLa 
cells.
A priori, the IF results may suggest some target 
preference for ATI members: for example, ATI 10 may 
bind to exposed tubulin on early MT polymerization 
products and inhibit their elongation, whereas the six-
atom ring ATIs (57, 33 and 44) may bind soluble tubulin 
and prevent its polymerization altogether. We examined 
phenotypes in cells exposed to varying concentrations 
of individual ATIs. Raising ATI 5 from 100 to 200 nM 
abolished the formation of asters and shifted the phenotype 
towards the formation of unstructured tubulin foci 
(“spots”) (Figure 4A, panels c-d). Conversely, lowering 
ATI 44 to 20 nM prevented the appearance of amorphous 
tubulin aggregates, i.e. the most severe phenotype, and 
also yielded tubulin foci (Figure 4A). Thus, the phenotypes 
in Figure 4A represent progressive stages of MT damage. 
Their concentration dependence suggests increasing scales 
of affinity of different ATIs, rather than distinct tubulin 
binding preferences.
We wondered whether the MT asters generated by 
ATIs 5 and 10 reflected the formation of supernumerary 
centrosomal MT-organizing centers (MTOCs) during 
prolonged treatment. Co-staining for alpha-tubulin 
(MTs) and gamma-tubulin (the most abundant MTOC 
component) revealed many asters in single prometaphase-
arrested cells, while gamma-tubulin staining identified 
only two canonical MTOCs (Figure 4B). Thus, the 
formation of MT asters is not dependent on their physical 
association with centrosomal MTOCs, indicating that 
ATIs induce neither overduplication nor fragmentation 
of centrosomes. In a normal mitosis, kinetochores 
(KTs) stabilize MTs that come in contact with them and 
induce the nucleation of MTs that contribute to spindle 
formation. This pathway becomes particularly evident 
when centrosomal MT nucleation is impaired, and indeed 
several MT-damaging agents induce the formation of 
non-centrosomal asters [49–53]. We found that ATI 
10-induced asters are composed of short MTs focused at 
one end, while the opposite end associates with CENP-A 
(the KT-associated nucleosomal histone) and with the 
SAC component BUB1 (Figure 4B). Thus, the short 
MTs interact with chromosomal KTs that stabilize them, 
but cannot grow to form a spindle. BUB1 signals on 
chromosomes indicates sustained SAC activation.
In wash-out experiments, cultures treated with 
the mild ATIs 5 and 10 showed faster progression from 
Figure 4 (Continued ): C. Frequency of increasingly severe MT-inhibitory phenotypes (histograms) induced by ATIs. Mean and SD 
values were calculated from 2 to 10 experiments per condition (at least 100 counted cells per experiment).
Oncotarget19746www.impactjournals.com/oncotarget
(G2+M) phase arrest compared to cultures treated with 
the six-atom ring ATIs 57, 33 and 44 (Supplementary 
Figure 1A). By IF analysis, mitosis resumption from MT 
asters yields grossly normal bipolar spindles, suggesting 
that the asters rapidly coalesce in two poles after ATI 
removal. Mitotic resumption from unstructured tubulin 
foci was slower and more prone to originate an abnormal 
mitotic apparatus, with persisting defects in chromosome 
segregation (Supplementary Figure 1B, compare mitosis 
resumption in the first three hours after wash-out of ATI 
10, that had prevalently induced MT asters, to that of ATI 
57-treated cultures, where mitotic cells had mostly arrested 
with unstructured tubulin foci. Higher resolution pictures 
are shown in Supplementary Figure 1C). Interestingly, 
cultures treated with ATIs 57, 44 and 33 showed largely 
defective reformation of the mitotic apparatus after wash-
out, and still underwent cell death 24 hours after ATI 
removal (Supplementary Figure 1D).
ATIs generate defective mitotic phenotypes in 
HT29 colorectal adenocarcinoma cells
The IF assays in HeLa cells suggest that the 
effectiveness of cell death induction by ATIs mirrors 
the severity of the mitotic inhibitory phenotypes that 
they induce. To assess the generality of this conclusion, 
we extended the experiments to HT29 colorectal 
adenocarcinoma cell lines, a widely used cellular model 
for its sensitivity to classical MT-inhibitory drugs [54].
The results in Figure 5 confirm the same hierarchical 
scale of MT inhibitory strength as in HeLa cultures. 
Mitotic phenotypes detected by IF in HT29 cultures 
are exemplified in Figure 5A and quantified in Figure 
5B. ATI 44 and, even more effectively, ATI 33 (both 
used 50 nM) prevalently induced prometaphase arrest 
with completely diffuse tubulin. ATI 57 induced mitotic 
defective phenotypes with either diffuse tubulin, or with 
tubulin foci, in comparable proportions. With ATI 10 
tubulin foci became the prevalent phenotype, with some 
cells also displaying small MT asters. The hierarchical 
strength in tubulin inhibition demonstrated by ATIs in 
HT29 cells correlated with their ability to induce cell 
death (by FACS measurements of the sub G1 fraction, 
Figure 5C). ATI 10, which displayed the mildest mitotic 
inhibitory power, induced the lowest fraction of cell death 
compared to other ATIs. Instead, ATIs 57 (100 nM), 44 
and 33 (the latter two used 50 nM) induced significant 
cell death, in the same range as VBL. Dose-response 
assays with ATI 10 (Supplementary Figure 2) showed 
that, in this sensitive cell line, the mild ATI 10 arrested 
cells in (G2+M) phases above 75 nM. MTs were generally 
damaged, preventing progression through mitosis and 
causing the (G2+M) accumulation detected by FACS. IF 
assays however revealed that treatment with 75, 100 or 
150 nM ATI 10 yielded a remarkably different distribution 
of mitotic phenotypes: the formation of multiple MT 
asters was prevalent (73% of all mitosis-arrested cells) in 
samples treated with 75 nM, decreased to 26% in samples 
treated with 100 nM, and disappeared almost completely 
in samples treated with the 150 nM concentration, at 
which dose 90% of mitotic cells showed no discernible 
tubulin residual structure but sparse spots. That phenotype 
represents the most severe damage produced by ATI 10. 
Though still less severe than that produced by the six-atom 
substituted ATIs, it is clearly more predictive of cell death 
than the simple induction of (G2+M) arrest (Supplementary 
Figure 2B). These experiments confirm and extend the 
results obtained in HeLa cells. We conclude that ATIs 
can effectively block mitotic progression, yielding (G2+M) 
arrest, by inducing mitotic MT inhibition to a varying 
extent. That however does not necessarily activate 
death signals, as cell death induction is associated with 
inhibitory phenotypes of increasing cytological severity.
ATI members induce distinctive cell fate profiles 
in time-lapse recording assays
To assess more directly the link between mitotic MT 
damage and cell death induction, we decided to record 
live cell cultures during exposure to ATIs by time-lapse. 
In initial experiments we used a HeLa cell line expressing 
H2B-red Cherry histone to visualize chromosomes and 
EGFP-tubulin to visualize MTs [55]. Cells were exposed 
to ATIs that induce either mild (ATI 10) or strongly 
defective cytological phenotypes (ATI 44) by IF, or VBL 
for comparison, and were recorded from the time of drug 
administration (protocol in Figure 6A). That enabled us 
to focus on early time points. Under all conditions, cells 
progressed from whichever cell cycle stage they were at 
the time of drug administration up to mitotic entry. Most 
control cells accomplished mitosis in less than 2 hours 
(see for example Figure 6B): because cells regularly 
enter and exit mitosis in DMSO-treated control cultures, 
the mitotic index remains constant from the time of 
DMSO administration (time 0) over the next 32 hours 
(Supplementary Figure 3A). Cultures exposed to ATI 44 
(50 nM), ATI 10 (100 nM), or VBL entered mitosis with 
a timing that was practically indistinguishable compared 
to controls, but remained blocked soon after round up in 
early prometaphase, and progressively accumulated in 
that stage (Supplementary Figure 3A). VBL and ATI 44 
induced sustained mitotic arrest (Supplementary Figure 
3B): treated cells that entered mitosis early during the 
video, i.e. 0 to 4 hours after drug administration, remained 
arrested throughout the recording time (over 20 hours). A 
fraction of cells were arrested 10 to 20 hours, and a minor 
fraction, corresponding to cells that entered mitosis late 
during the video, were arrested for 5 hours or less. ATI 10 
induces a slightly lower fraction of stably arrested cells 
(>20 hour-long arrest). Given that the drugs do not induce 
significant differences in mitotic entry, the data indicate 
that ATI 10 tends to induce less sustained mitotic arrest, 
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Figure 5: Abnormal MT phenotypes and cell death induction by ATIs in HT29 colorectal carcinoma cell cultures. A. 
Representative examples of mitotic phenotypes induced by ATIs in HT29 cell cultures (MTs are visualized by FITC-conjugated anti-alpha-
tubulin antibody in green and chromosomes by DAPI staining in blue). From left to right, mitotic phenotypes are arranged according to their 
increasing intensity. The prevalent induction of particular phenotypes by individual ATIs is indicated below. Bar, 5 μm. B. The histograms 
represent the frequency of the mitotic phenotypes illustrated in A after treatment with the indicated ATIs. C. The histograms represent the 
% of PI-stained cells with a <2C DNA content in ATI-treated HT29 cells after FACS analysis. For all assays, means and SD values were 
calculated from three independent experiments.
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Figure 6: Single cell analysis of video-recorded cells in HeLa/H2B-mCherry/alpha-tubulin-EGFP treated cultures. 
A. Time-lapse protocol used to record HeLa/H2B-mCherry/alpha-tubulin-EGFP cultures treated with MT-targeting drugs. Cultures were 
recorded form the time of drug addition (time 0) over the next 48 hours. B. Representative control cell (DMSO-treated) undergoing normal 
division. Phase contrast pictures, chromosomes (H2B-mCherry) in the red fluorescence channel, and alpha-tubulin in the green fluorescence 
channel are shown. C. Cell exposed to 50 nM ATI 10, showing prometaphase delay followed by aberrant mitotic exit without division, 
readhesion and generation of a multinucleated cell. D. Still frames depicting cell death during mitotic arrest in a cell treated with 100 nM 
ATI 10. Bars, 10 μm. 
(Continued )
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Figure 6 (Continued ): E. The panels represent the fate of single cells in cultures treated as indicated. Each line depicts a single HeLa/
H2B-mCherry/alpha-tubulin-EGFP cell. F. The histograms represent the frequency of terminal fates recorded in control (DMSO) and 
treated cultures. The number of recorded cells in two independent time-lapse assays are shown above each histogram.
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with some cells eventually readhering to the culture dish 
after either aberrant or failed division after prolonged 
mitotic delay (see for example Figure 6C).
To gather information on the terminal fates of the 
cells we recorded single cell fates induced by ATIs 10 
and 44, at two different concentrations, during 48 hours 
from the time of drug addition. The recorded individual 
cell fates are plotted in Figure 6E. The EGFP fluorescence 
associated with depolymerizing tubulin in vivo was not 
amenable to detailed resolution of the MT damage type in 
video-recording, yet interesting information was obtained. 
50 nM ATI 10 induced most treated cells to divide 
aberrantly. Some daughter cells activated cell death after 
the abnormal division, yet a significant fraction re-entered 
the cell cycle and divided abnormally again. Elevating the 
concentration of ATI 10 to 100 nM remarkably reduced 
that cell population: abnormal divisions still occurred, yet 
many cells proficiently activated mitotic cell death (Figure 
6D shows a cell undergoing death during sustained mitotic 
arrest, with intensely fluorescent fragmented nuclei). In 
cultures treated with ATI 44 (20 nM) abnormal divisions 
still took place, but were almost invariably followed by 
death of the daughter cells. A fraction of treated cells failed 
to divide and, after prolonged mitotic arrest, readhered 
and thereafter underwent death. Raising ATI 44 to 50 nM 
suppressed many intermediate cellular fates and induced 
death in most mitotic-arrested cells. These initial recording 
assays link the capacity of ATIs to induce cell death to 
the severity of induced MT damage (Figure 4) and hence 
the induction of sustained mitotic arrest (Figure 6E). We 
therefore recorded systematically the fate of cells treated 
with each of the five ATIs under the same conditions under 
which we had characterized their MT-damaging strength 
(Figure 4). Because the use of EGFP-tubulin might have 
added an additional level of phototoxicity, complicating 
the interpretation of the effects of the ATIs over MTs, we 
used a HeLa-derived cell line expressing only H2B-GFP 
to visualize chromosomes.
Figure 7A shows an untreated H2B-GFP/HeLa 
cell dividing normally. Occasionally, some cells that 
reached mitosis late during videorecording divided along 
a multipolar axis (see for example Figure 7B), or left 
unresolved chromatin bridges between daughter cells. 
A small fraction of cells remained arrested in mitosis 
throughout the video, possibly reflecting hindrances 
in completing mitosis during medium exhaustion. 
We next recorded treated cultures, and included TAX 
for comparison, the effects of which are extensively 
characterized [28, 56–57].
With either TAX or VBL treatment (protocol in 
Figure 8A), most cells that reached mitosis during the 
first 24 hours of recording became stably arrested soon 
after round up, then underwent diversified fates (Figure 
8B, left panel, VBL; right panel, TAX). A fraction (16-
18% with both TAX and VBL) remained durably arrested 
throughout the video. Many cells activated the death 
pathway during mitotic arrest. A fraction (over 30% with 
either drug) exited mitosis after a variable delay and 
generated abnormal products with either unsegregated, 
or randomly segregating chromosomes. Many of these 
abnormal mitotic products died in the next interphase, but 
about 30% remained apparently viable. These experiments 
define the window from 24 to 48 hours after drug addition 
as most informative. They also identify distinctive 
phenotypes that followed MT inhibition, but not MT 
hyperstabilization. Indeed, VBL triggered an array of cell 
fates in cells that entered mitosis, yet with specificities 
compared to TAX: first, VBL-arrested prometaphases 
underwent rapid changes in cell shapes and projection of 
cytoplasmic protrusions that were not observed in TAX-
treated cultures. Second, some VBL-treated cells that 
experienced a long prometaphase delay failed to initiate 
chromosome segregation and eventually readhered to 
the culture dish and decondensed chromosomes in an 
undivided cytoplasm (as previously described in the 
H2B-mCherry/EGFP-tubulin cell line in Figure 6). 
Both processes, i.e. the cytoplasmic protrusions and the 
readhesion without division, are specific responses to MT 
depolymerization and are not seen with TAX.
We finally recorded ATI-treated samples, 
focussing on the 24-48 hours after treatment to minimize 
phototoxicity (Figure 8A). The lower panels in Figure 
8B represent the fate of single recorded cells. These 
assays confirmed that ATI 10 transiently arrested mitosis, 
yet only a relatively small fraction of cells (about 11%) 
underwent death in mitosis, preceded by a highly intense 
blebbing activity (see Figure 7D). About one third of 
the cells resumed mitosis after prolonged prometaphase 
delay. About 14% of these cells divided abnormally after 
prometaphase arrest and generated aberrant products (see 
for example Figure 7C), a fraction of which died in the 
next interphase.
ATI 5 (100 nM) yielded more diversified cell fates. 
Almost half of the cells that entered mitosis remained 
durably arrested in prometaphase, and about 35% 
died during prometaphase arrest. A fraction eventually 
bypassed the arrest and divided aberrantly, often followed 
by fusion of the cell division products (Figure 7C). We 
also noted that some mitotic cells (about 5%) readhered 
after prolonged prometaphase, as seen with VBL. These 
cells are tetraploid, hence genetically similar to the group 
that re-fused after segregation. Time-lapse recording 
reveals however some functional diversity between 
the re-adhesion phenotype (no attempt of chromosome 
segregation with re-adhesion in prometaphase) and the 
class represented in Figure 7C (aberrant chromosome 
segregation in anaphase, followed by the failure to 
terminate cell division and fusion of the generated 
products): different stages of mitosis are impaired, 
respectively early (prometaphase) and late (final 
cytokinesis), possibly reflecting differential mitotic MT 
inhibition in individual cells.
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Figure 7: In vivo imaging of mitotic cell fates induced by ATIs in HeLa/H2B-GFP treated cultures. A. Still frames from 
a recorded HeLa/H2B-GFP cell undergoing mitosis with a normal timing. Cell division is complete in about one and a half h after the 
onset of mitotic round-up (taken as time 0). The timing of mitotic phases recorded from 163 cells is shown on the right. B. Still frames 
from an exemplifying videorecorded cell exposed to ATI 10 showing transient delay in prometaphase, then reaching multipolar alignment 
and undergoing aberrant mitotic exit followed by fusion to form a single multinucleated cell. C. Still frames from a videorecorded HeLa/
H2B-GFP cell treated with ATI 10 undergoing prolonged delay in prometaphase (up to 1500 min from the onset of recording), followed 
by intensely dynamic blebbing and abnormal mitotic division; the two unequal mitotic products eventually readhere and appear to reenter 
interphase. D. Still frames from a videorecorded HeLa/H2B-GFP cell treated with ATI 33, exemplifying death during mitotic arrest.
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Figure 8: Single-cell analysis of video-recorded cell fates induced by ATIs. A. Protocol for cell fate recording in HeLa/
H2B-GFP cultures treated with MT-targeting drugs. B. The panels represent the fate of individual cells that either enter mitosis, or die in 
interphase, in samples treated with the indicated drugs. Each line in the panels depicts a single HeLa/H2B-GFP cell in the 24-48 hours time 
window post-treatment. Cells were recorded in at least 3 time-lapse assays for each ATI and 2 for VBL and TAX; total number of cells are 
indicated. The ATI 5 panel is depicted in a 50% reduction. C. The histograms represent the frequency of terminal fates in cells that enter 
mitosis (numbers are shown above each histogram) in control (DMSO) and treated HeLa/H2B-GFP cultures.
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Both ATI 33 and 44 (50 nM, yielding the formation 
of tubulin aggregates in IF assays) arrested many cells 
in early mitosis in the recording assays. Prometaphase-
arrested cells underwent rapid formation and projection 
of protrusions, more pronounced and prolonged than 
recorded with other ATIs. This often evolved in mitotic 
death: over 40% of cells died in mitosis with ATI 44 and as 
many as 70% with 33, which consistently proved the most 
severely MT-damaging ATIs. Some cells treated with both 
drugs either re-adhered while in prometaphase, or divided 
aberrantly, often followed by death in the next interphase. 
A fraction of the cells (24% with ATI 44 and 16% with 
33) were still stably blocked in mitosis after 48 hours of 
treatment. ATI 33 yields a lower frequency of abnormal 
divisions and higher death in mitosis compared to ATI 
44. The frequency of the terminal cell fates in treated 
populations is schematized in Figure 8C.
In summary, all ATIs arrest mitosis and establish 
conditions for an array of possible fates. The recording 
data depict specific differences in the ratio of mitotic death 
to prolonged mitotic arrest, with the latter potentially 
exiting in abnormal mitotic division, re-adhesion to form 
multinucleated cells, or post-mitotic death. They depict a 
parallel between the evolution of cell fates and the type of 
MT cytological phenotype induced by distinct ATIs and 
identify death in mitosis as the prevalent fate induced by 
the 6 atom-ring ATIs. Collectively, the data indicate that 
the severity of MT damage (Figure 4) is a better predictor 
of mitotic cell death induction by tubulin inhibitory drugs 
compared to their cell cycle effects, which in can be 
apparently similar (Figure 2).
DISCUSSION
Tubulin-targeting molecules are actively being 
designed and assayed in various types of cancer cell 
lines, yielding consistent arrest of cell cycle progression, 
confirming that mitosis remains a valuable cancer 
therapeutic target. It is proposed that the “ideal” anti-
mitotic drug should arrest cancer cell division and induce 
death in mitosis to prevent the generation of genetically 
unbalanced, hence unstable, cells - which may cause 
aggressive tumor progression and relapse over time. 
The issue of the sensitivity of cancer cells to anti-mitotic 
drugs is being intensely investigated. Both the genetic 
background of the cancer cells, and the expression profile 
of genes encoding MT-regulatory factors, influence 
the ultimate outcome of MT-targeting molecules [12]. 
The development of single cell methods also growingly 
underscores ample variations in the response of single 
cells, even with identical genetic background [26–27, 58], 
adding an additional layer of complexity in predicting the 
cancer cell response.
Here we have selected five structurally related ATI 
molecules endowed with similar in vitro tubulin binding 
properties, similar competitive inhibition of Colchicine 
biding to tubulin, and grossly similar growth suppressive 
effects in conventional cell toxicity assays [33–35]. 
Such compounds share a consistent binding mode at the 
Colchicine site. Docking experiments (Figure 9) highlight 
some common interactions: an H-bond with αThr179; a 
polar contact between βCys241 and methoxy moieties; the 
trimethoxyphenyl group formed hydrophobic interactions 
with βLeu248, and βLeu255; the 5- and 6- member rings 
at position 2 of the indole set up hydrophobic interactions 
with the βLys254 and βLeu248 side chains; the indole ring 
established contact with βLys353 side chain (Figure 9A). 
The binding of Colchicine is modeled in Figure 9B for 
comparison.
All ATIs yielded an accumulation of cells with a 4C 
genomic content, as a result of mitotic arrest or delay in 
treated cell populations. Different ATIs displayed however 
a differential MT inhibition capacity in mitotic cells, that 
was hierarchically distinguishable at the cytological level 
in dose-dependent assays. It is possible, in principle, 
that different ATIs have differential pharmacokinetics 
properties at the single cell level, and that this contributes 
to the observed differences both between structurally 
similar ATIs, and in individual cells exposed to the same 
ATI. At the cytological level, we found that ATIs carrying a 
five-atom ring (ATI 5 and 10) allowed some degree of MT 
polymerization, with the formation of either multipolar 
spindles (lacking structural cohesion at the spindle pole 
level), or asters of short radially arranged MTs. The 
asters were associated with KT proteins through the MT 
outer ends, suggesting that they reflect the activation of 
the MT nucleation pathway driven by KTs. Raising the 
concentration of the aster-inducing ATIs inhibited tubulin 
polymerization more extensively, with only sparse foci 
remaining visible. ATI molecules carrying a six-atom ring 
at position 2 of the indole, particularly ATIs 33 and 44, 
proved highly effective tubulin inhibitors, preventing MT 
assembly in the 20-50 nanomolar range, similar to VBL. 
Higher concentrations yielded a meshwork of aggregate-
like structures. Thus, although in vitro properties would 
not have predicted dramatically different MT inhibitory 
capacity for these molecules, IF analysis depicted 
significant differences in cells. These differences were 
consistently observed in HeLa cervix carcinoma and HT29 
colorectal adenocarcinoma cell lines. Retrospectively, the 
alpha-tubulin IF pattern induced by specific ATIs provides 
a more accurate basis for predicting the treatment outcome 
in dividing cells. We suggest that the appearance of tubulin 
aggregates, or unstructured tubulin spots, or MT asters, 
which directly visualize the extent of the cell growth-
inhibitory properties of ATIs, can provide a rapid test to 
predict the effectiveness of MT-inhibitory drugs at any 
given concentration.
Time-lapse recording assays depicted variations 
within HeLa cultures in response to one same compound. 
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ATIs generally activated a proficient SAC response, 
and most treated cells induced prolonged arrest in 
prometaphase, with condensed chromosomes and no, 
or defective, MTs. ATIs that induced a relatively “mild” 
cytological phenotype induced only a transient mitotic 
delay. Eventually cells exited mitotic arrest along two 
major processes: i) resumption of mitosis in the absence 
of a functional mitotic apparatus, followed by aberrant 
segregation and generation of aneuploid cells, or ii) failure 
to complete mitotic division and cytokinesis, followed by 
readhesion with an undivided cytoplasm and generation 
of a polyploid cell. After slippage, a fraction of the newly 
generated cells die in the following interphase. It is now 
known that MT-targeting drugs activate death pathways 
that rely on the activation of a DNA damage response 
during prolonged mitotic delay [59–62], which triggers 
factors important for post-mitotic death. It is unclear how 
post-mitotic death is induced in HeLa cells, which lack 
functional p53 due to expression of the E6 inactivating 
antigen. Our time-lapse assays recorded a frequent failure 
of segregation of H2B-GFP labeled-chromosomes, 
suggesting that heavy mis-segregation and genetic 
unbalance of the cell division products causes their loss of 
viability, regardless of p53 function.
The six atom-ring ATIs induce rare mitotic 
slippage and, consequently, rare post-mitotic cell death 
events. They rather activate death in prometaphase-
arrested cells, especially ATI 33. The effectiveness 
of this pathway in HeLa cells suggests that cell death 
is p53-independent. Western blot assays indicate that 
ATIs induce the activation of BAX and CASP3 and 
-9, as well as massive downregulation of MCL-1 and 
phosphorylation (an inactivating modification) of BCL-
2. MCL-1 downregulation and CASP3 activation are 
particularly significant in cultures treated with ATIs 57, 
44 and 33, suggesting that ATI-dependent cell death relies 
particularly on mechanisms mediated by these factors. 
Indeed, we find that CASP3 is essential for non-necrotic 
death induction in ATI-treated cells. Interestingly, the 
bis-indole KAR-2, a derivative of VBL, causes a rise 
in intracellular Ca(2)+ levels [63], similar to other MT-
destabilizing agents. Ca(2)+ release can directly modulate 
cell death. In addition, Ca(2)+ levels can fragilize MTs 
and hence cooperate with MT-inhibitory molecules in 
disrupting mitotic spindle function and structure, thus 
reinforcing the cell death signals initiated by MT damage. 
It might be speculated that ATIs can also differentially 
modulate intracellular Ca(2)+ release, which might in turn 
modulate cell death. On the whole, the results presented 
here indicate that the severity of induced MT damage by 
individual ATIs is a more effective trigger of mitotic cell 
death than the length of mitotic arrest per se, suggesting 
that the threshold for emanating death signals by MT 
damage can be predicted from accurate IF characterization 
of the cytological phenotypes.
Time-lapse recording is extensively used to depict 
the unfolding of dynamic programs and/or response to 
particular conditions, but is employed surprisingly poorly 
Figure 9: Predicted binding modes for ATIs and Colchicine by molecular modeling. A. Modeling of the ATI-binding site on 
tubulin. Tubulin is depicted as a yellow ribbon and specific ATI compounds as sticks of different color: ATI 5, pink; ATI 10, gray; ATI 33, 
magenta; ATI 44, cyano; ATI 55 green. H-bond is depicted as a dotted yellow line. B. Modeling of the Colchicine-binding site on tubulin. 
Colchicine is depicted as a lilac stick. Residues involved in contacts are shown as white lines.
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in drug design and validation studies, although the trend is 
increasing. Studies of new drugs typically examine whole 
cell-level responses in cultured cells, e.g. the overall cell 
cycle and cell death profiles, and/or biochemical studies 
of the chosen target, then often move to preclinical 
studies in animal models. That typical protocol misses 
out information on the dynamics and heterogeneity of the 
response of individual cells. For example, assays of the 
mitotic kinase Aurora-A inhibitor MLN8237 (Alisertib), 
did not include videorecording data prior to undergoing 
pre-clinical and phase I-III clinical trials. Recording 
methods later depicted heterogeneous cell fates, with 
possibly detrimental consequences (low mitotic death, 
high aneuploidy induction), that had not been originally 
appreciated [64]. The present results further highlight 
methodological caveats in bulk cell population analyses. 
Coupling mitotic phenotypes and single-cell recording 
data provides reliable informative tools to characterize 
potentially interesting compounds that may undergo 
further levels of validation.
In conclusion, the data presented in this work 
pinpoint the effectiveness of members of the six-atom 
ring ATIs in triggering death in mitosis in the nanomolar 
range, comparable to, or higher than, canonical MT-
targeting inhibitors such as VBL, yielding little mitotic 
slippage or multipolar divisions. These ATIs can represent 
a valuable addition to increase the molecular diversity of 
MT-targeting agents.
MATERIALS AND METHODS
Compounds
ATIs were synthesized at the Drug Design and 
Synthesis Center of Sapienza University of Rome as 
described previously [33–35]. VBL (sulfate salt, Sigma 
V1377), CA-4 (Sigma C7744) and TAX (Selleck S1150) 
and all ATIs were dissolved in DMSO (Sigma, 472301; 
0.1% final concentration). In comparative studies, ATIs 
were used 100 at nM unless otherwise indicated. TAX 
was used at 100 nM. VBL and CA-4 at 20 nM. In all 
experiments control cultures were treated with 0.1% 
DMSO.
Cell cultures and treatment
HeLa cervix carcinoma, HeLa/H2B-mCherry/alpha-
tubulin-EGFP [55], HT29 colorectal adenocarcinoma 
and MCF7 breast carcinoma cell lines were from ATCC 
(American Tissue Culture Collection). The MCF7/
CASP3 cell line reconstituted with caspase-3 was a 
kind gift from Dr. Christopher J. Froelich (North Shore 
University, Health Systems Research Institute, Evanston, 
IL, USA) [46]. The HeLa-derived cell line stably 
transfected with H2B-GFP was described [65]. Cell lines 
were all grown in Dulbecco’s Modified Eagle medium 
(D-MEM) supplemented with 10% fetal calf serum (20% 
for MCF7/CASP3), 2% L-glutamine and 2% penicillin/
streptomycin, at 37°C with 5% CO2. In order to maintain 
HeLa/H2B-mCherry/alpha-tubulin-GFP cell line, 0.5 μg/
ml puromycin (Clontech, 631305) and 0.5 μg/ml G418 
(Sigma, A1720) were used. In experiments with all cell 
lines 300,000 cells were plated in 9 cm2-culture dishes and 
treated with MT-targeting compounds for 24 hours unless 
indicated otherwise.
FACS analysis
Cell cycle phase distribution was analyzed after 
incubation with propidium iodide (PI, Sigma P4170). 
All parameters (FS, SS and FL-3) were acquired in a 
linear amplification scale. Cell aggregates were gated 
out on the bi-parametric graph FL-3lin/Ratio. Cell death 
was analyzed after incubation with Annexin V-FITC 
(Immunofluorescence Science, IK-11120), either alone 
or in combination with PI. In the latter case, both FL-1 
(FITC) and FL-3 (PI) were acquired in a log amplification 
scale. Cell samples were analyzed in a Coulter Epics XL 
cytofluorometer (Beckman Coulter) equipped with EXPO 
32 ADC software. At least 10,000 cells per sample were 
acquired. Data were processed using EXPO 32 ADC or 
Win MDI software.
Western blotting
HeLa cell cultures were exposed to either solvent 
(0.1 % DMSO), or TAX, VBL and each of the ATIs at 
the indicated concentrations. After 24 hours protein 
extracts were separated through SDS-polyacrylamide 
gel electrophoresis, transferred to nitrocellulose filters, 
blocked and incubated with the following primary 
antibodies, all screened using TAX-treated extracts: 
mouse anti-MCL-1 (22) (sc-12756, 1:200 over night), 
mouse anti-BCL-2 (C-2) (sc-7382, 1:500 over night), 
mouse anti-BAX (B-9) (sc-7480, 1:500 over night) and 
goat anti-actin (I-19) (sc-1616, 1:400), all from Santa 
Cruz Biotechnology; rabbit anti-cleaved Caspase-3 
(Asp175) (#9661, 1:500 over night) and rabbit anti-
Caspase-9 (#9502, 1:1000 over night) both from Cell 
Signaling Technology (Danvers, MA, USA). Horseradish 
peroxidase-conjugated secondary antibodies (goat anti-
mouse 1:10000 for anti-MCL-1 and anti-BAX or 1:2000 
for anti-BCL-2, goat anti-rabbit 1:2000 and donkey anti-
goat 1:5000 from Santa Cruz Biotechology) were revealed 
with enhanced chemiluminescence (ECL) or ECL plus 
(GE Healthcare, Chalfort Saint Giles, UK).
Immunofluorescence
After treatment, cells grown on sterile poly-L-lysine 
(Sigma P4832) coated coverslips were fixed in 100% 
methanol (6 min, -20°C). Primary antibodies were: alpha-
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tubulin, either unconjugated (B5-1-2) or FITC-conjugated 
(DM1A), both from Sigma; Bub1 (Millipore, MAB3610); 
CENP-A (Abcam, mouse monoclonal 13939); gamma-
tubulin (Sigma-Aldrich, GTU-88). Secondary antibodies 
were conjugated to FITC or Cy3 (Jackson Immunoresearch 
Laboratories), Texas Red (Vector Laboratories), or AMCA 
(Santa Cruz Biotechnology). DNA was stained with 0.05 
μg/ml DAPI (Sigma D9542) and coverslips were mounted 
in Vectashield (Vector Laboratories).
Microscopy
IF processed cell preparations were examined 
under an epifluorescence microscope Nikon Eclipse 90i 
equipped with a QICAM Fast 1394 camera (QImaging) 
using the NIS-Elements AR 3.2 software (Nikon). Single 
cell images were routinely taken using immersion oil 100x 
objectives with NA 1.3. 0.3 or 0.6-μm z-serial optical 
sections were processed using either the “Deconvolution 
module” (NIS-Elements AR3.2, Nikon) or the “AutoQuant 
module” (NIS-Elements AR4, Nikon). Processed images 
using deconvolution algorithms were flattened using the 
Extended Depth of Focus tool.
Time-lapse recording
HeLa/H2B-GFP and HeLa/H2B-mCherry/alpha-
tubulin-EGFP cells were seeded in glass-bottomed 3.5 cm 
plates (Ibidi 81158) or μ-Slide (chambered coverslip) with 
4/8 wells (80426/80821, IbiTreat, Ibidi). During recording, 
cell cultures were kept at 37° C in a temperature- and 
CO2 controlled microscope stage incubator (Basic WJ, 
Okolab). Cultures were recorded under an automated 
inverted microscope (Ti Eclipse, Nikon) equipped with a 
DS-Qi1MC camera, an Intensilight C-HGFIE lamp, and 
the NIS-Elements 3.2 software (all from Nikon). Phase-
contrast (60x 0.7 NA) or immersion oil (60x 1.4 NA) 
objectives were used. Most recording experiments were 
carried out for 48 hours as indicated in the text. In the 
HeLa/H2B-GFP cell line, differential interference contrast 
(DIC) images were taken every 3 min and GFP images 
every 20 or 21 min. In the HeLa/H2B-mCherry/alpha-
tubulin-EGFP cell line, Phase (Ph) images were taken 
every 3 or 5 min, GFP and mCherry images every 25 min.
Molecular modeling
Docking experiments were carried out following a 
previously reported procedure [33–35, 37]. Figure 9 was 
created using Pymol (www.pymol.org).
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